Nwam LLC Purchases 504 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Nwam LLC increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 18.4% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,244 shares of the medical research company’s stock after buying an additional 504 shares during the quarter. Nwam LLC’s holdings in Thermo Fisher Scientific were worth $1,693,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. Arrowstreet Capital Limited Partnership boosted its stake in shares of Thermo Fisher Scientific by 3.7% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 681,679 shares of the medical research company’s stock worth $392,899,000 after buying an additional 24,376 shares during the last quarter. American Trust grew its stake in Thermo Fisher Scientific by 13.2% in the first quarter. American Trust now owns 6,743 shares of the medical research company’s stock valued at $3,886,000 after purchasing an additional 784 shares in the last quarter. Sterling Investment Management LLC acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $1,074,000. Alta Capital Management LLC boosted its holdings in shares of Thermo Fisher Scientific by 5.1% in the 2nd quarter. Alta Capital Management LLC now owns 88,286 shares of the medical research company’s stock valued at $46,064,000 after buying an additional 4,307 shares during the last quarter. Finally, First Manhattan CO. LLC. grew its stake in shares of Thermo Fisher Scientific by 11.2% in the first quarter. First Manhattan CO. LLC. now owns 724,844 shares of the medical research company’s stock valued at $417,779,000 after buying an additional 72,792 shares in the last quarter. 87.06% of the stock is owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 3,000 shares of the business’s stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $557.77, for a total transaction of $1,673,310.00. Following the sale, the executive vice president now owns 17,556 shares in the company, valued at approximately $9,792,210.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $454.41, for a total transaction of $4,544,100.00. Following the sale, the chief executive officer now directly owns 131,175 shares of the company’s stock, valued at approximately $59,607,231.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 3,000 shares of the firm’s stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $557.77, for a total transaction of $1,673,310.00. Following the transaction, the executive vice president now directly owns 17,556 shares of the company’s stock, valued at approximately $9,792,210.12. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 23,000 shares of company stock worth $10,778,910. Corporate insiders own 0.32% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on TMO. Royal Bank of Canada cut their price target on shares of Thermo Fisher Scientific from $657.00 to $579.00 and set an “outperform” rating for the company in a research note on Thursday, October 26th. StockNews.com upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Thursday, October 26th. Citigroup dropped their price objective on Thermo Fisher Scientific from $625.00 to $530.00 and set a “buy” rating on the stock in a research note on Thursday, October 26th. Barclays decreased their target price on Thermo Fisher Scientific from $625.00 to $585.00 in a report on Friday, September 29th. Finally, Morgan Stanley cut their price target on Thermo Fisher Scientific from $640.00 to $600.00 and set an “overweight” rating for the company in a report on Tuesday, October 24th. Two research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $593.94.

Thermo Fisher Scientific Price Performance

TMO stock traded down $0.60 during mid-day trading on Thursday, hitting $469.94. The stock had a trading volume of 179,420 shares, compared to its average volume of 1,562,291. The firm has a fifty day simple moving average of $481.23 and a 200 day simple moving average of $515.47. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $609.85. The company has a current ratio of 1.63, a quick ratio of 1.25 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $181.57 billion, a P/E ratio of 30.84, a P/E/G ratio of 2.70 and a beta of 0.81.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 25th. The medical research company reported $5.69 earnings per share for the quarter, beating the consensus estimate of $5.61 by $0.08. The business had revenue of $10.57 billion for the quarter, compared to analyst estimates of $10.60 billion. Thermo Fisher Scientific had a return on equity of 18.88% and a net margin of 13.68%. Thermo Fisher Scientific’s revenue was down 1.0% compared to the same quarter last year. During the same period last year, the firm posted $5.08 earnings per share. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current year.

Thermo Fisher Scientific declared that its Board of Directors has approved a stock buyback program on Tuesday, November 14th that authorizes the company to buyback $4.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to repurchase up to 2.2% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s management believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, January 16th. Shareholders of record on Friday, December 15th will be given a $0.35 dividend. The ex-dividend date is Thursday, December 14th. This represents a $1.40 dividend on an annualized basis and a yield of 0.30%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.17%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.